Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CDK8 | P49336 | 8/20 | 0.39 |
| ▸ | CDK19 | Q9BWU1 | 8/20 | 0.39 |
| ▸ | CCNC | P24863 | 5/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | SMO | Q99835 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1096010 | 0.93 | LMNA (0.55) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL16001935 | 0.87 | CYP2D6 (0.43) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL25051771 | 0.87 | CYP2D6 (0.43) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL16564794 | 0.83 | LMNA (0.49) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL21776132 | 0.81 | LMNA (0.51) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL18355718 | 0.80 | LMNA (0.46) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL22770864 | 0.80 | — | — | |
| SCHEMBL20007955 | 0.80 | CYP2D6 (0.44) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL3062964 | 0.78 | LMNA (0.45) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL23542595 | 0.77 | LMNA (0.40) | LMNACHRM2ADRA2ACYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200062760-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
| WO-2018081091-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062760-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPRJ, PTPRC | LMNA 4793/4885CHRM2 4590/4885ADRA2A 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.